Abiraterone
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Abiraterone and local guidelines before prescribing.
Mechanism
Irreversible inhibitor of CYP17, blocking androgen synthesis in testes, adrenals and tumour.
Uses
Metastatic castration-resistant or high-risk hormone-sensitive prostate cancer, with prednisolone.
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Hypertension, hypokalaemia, fluid retention, liver enzyme rise, fatigue.
Interactions
CYP2D6 substrates (e.g. metoprolol) levels rise; strong CYP3A4 inducers lower levels.
Contraindications and cautions
Severe liver impairment; caution in heart failure, hypertension, hypokalaemia
Monitoring
BP, potassium, LFT, fluid status
Pregnancy and breastfeeding
Not for use in women; contraception needed by male partners
Renal and hepatic impairment
Reduce in moderate liver impairment; avoid in severe
Overdose and reversal
Supportive care
Special advice
Always given with a corticosteroid to limit mineralocorticoid excess; monitor BP, potassium, fluid status and LFTs.
More from the textbook: uses, cautions and other points
- Abiraterone (with prednisolone) - hypertension, low potassium, fluid retention, liver toxicity.
Oncology: Principles - Abiraterone (with prednisolone) | Hypertension, low potassium, liver toxicity.
Oncology: Principles - Plus a newer hormonal drug (abiraterone, enzalutamide, apalutamide or darolutamide), with or without docetaxel .
Oncology: Urology and Genital cancers - Abiraterone (with prednisolone) | Metastatic prostate cancer; hypertension, low potassium, liver toxicity.
Oncology: Urology and Genital cancers
Where it is discussed in the book
- Oncology: Principles (2 mentions)
- Oncology: Urology and Genital cancers (2 mentions)